Acute kidney injury in patients with malignancy: clinical characteristics, etiology and outcomes across KDIGO stages
DOI:
https://doi.org/10.18203/2349-3933.ijam20262828Keywords:
Acute kidney injury, KDIGO, MalignancyAbstract
Background: Acute kidney injury (AKI) is a frequent and serious complication in patients with malignancy, contributing to increased morbidity, mortality and adverse renal outcomes. This study evaluated the clinical profile, primary etiologies, laboratory characteristics and outcomes of oncology patients with AKI according to kidney disease. Improving global outcomes (KDIGO) staging.
Methods: This retrospective observational study included 100 adult oncology patients with KDIGO-defined AKI admitted between May 2021 and April 2026. Patients were classified as KDIGO stage 1 (n=30), stage 2 (n=35) or stage 3 (n=35). Demographic characteristics, comorbidities, primary etiologies, laboratory parameters and clinical outcomes were compared across AKI stages.
Results: Increasing AKI severity was associated with older age and a higher prevalence of diabetes mellitus, hypertension and hematological malignancies. Sepsis was the most common primary etiology of AKI across all stages. Progressive worsening of hematological, inflammatory, metabolic and biochemical parameters was observed with increasing KDIGO stage (all p<0.001). Complete renal recovery at discharge declined significantly from 83.3% in stage 1 to 20.0% in stage 3, while in-hospital mortality increased from 10.0% to 51.4% (p=0.001). Among hospital survivors, complete recovery at 3 months decreased from 88.9% to 29.4%, whereas progression to chronic kidney disease increased from 7.4% to 52.9% across stages 1 to 3 (both p<0.001). Hospital readmission was more frequent in patients with severe AKI (p=0.048).
Conclusions: Higher KDIGO stage is associated with greater clinical and biochemical derangement, reduced renal recovery, increased CKD progression and higher mortality in oncology patients with AKI. Early recognition and timely intervention may improve renal and patient outcomes in this high-risk population.
Metrics
References
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138.
Singer M, Deutschman CS, Seymour CW. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801-10. DOI: https://doi.org/10.1001/jama.2016.0287
Evans L, Rhodes A, Alhazzani W. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-247. DOI: https://doi.org/10.1007/s00134-021-06506-y
Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011;22(4):399-406. DOI: https://doi.org/10.1016/j.ejim.2011.05.005
Campbell GA, Hu D, Okusa MD. Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis. 2014;21(1):64-71. DOI: https://doi.org/10.1053/j.ackd.2013.08.002
Benoit DD, Hoste EA. Acute kidney injury in critically ill patients with cancer. Crit Care Clin. 2010;26(1):151-79. DOI: https://doi.org/10.1016/j.ccc.2009.09.002
Soares M, Salluh JI, Carvalho MS, Darmon M, Rocco JR, Spector N. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol. 2006;24(24):4003-10. DOI: https://doi.org/10.1200/JCO.2006.05.7869
Lupușoru M, Lupușoru G, Ailincăi I, Frățilă G, Andronesi A, Micu E, et al. Renal replacement therapy in cancer patients with acute kidney injury (Review). Exp Ther Med. 2021;22(2):864. DOI: https://doi.org/10.3892/etm.2021.10296
Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013;8(2):55870. DOI: https://doi.org/10.1371/journal.pone.0055870
Darmon M, Vincent F, Canet E, Mokart D, Pène F, Kouatchet A, et al. Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie. Nephrol Dial Transplant. 2015;30(12):2006-13. DOI: https://doi.org/10.1093/ndt/gfv372
Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019;38(3):295-308. DOI: https://doi.org/10.23876/j.krcp.19.042
Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, et al. Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study. J Natl Cancer Inst. 2019;111(7):727-36. DOI: https://doi.org/10.1093/jnci/djy167
Braet P, Re Sartò GV, Pirovano M. Treatment of acute kidney injury in cancer patients. Clin Kidney J. 2022;15(5):873-84. DOI: https://doi.org/10.1093/ckj/sfab292
Gupta S, Gudsoorkar P, Jhaveri KD. Acute kidney injury in critically ill patients with cancer. Clin J Am Soc Nephrol. 2022;17(9):1385-98. DOI: https://doi.org/10.2215/CJN.15681221
Can W, Rong L, Lixia L. Incidence and risk factors of acute kidney injury in patients with malignant tumors: a systematic review and meta-analysis. BMC Cancer. 2023;23:1123. DOI: https://doi.org/10.1186/s12885-023-11561-3
Calças Marques R. Severe acute kidney injury in hospitalized cancer patients. Cancers (Basel). 2024;16(3):561. DOI: https://doi.org/10.3390/cancers16030561
Nazzal Z. The rate and risk factors of acute kidney injury among cancer patients' admissions in Palestine: a single-center study. Int J Nephrol. 2022;2:2972275. DOI: https://doi.org/10.1155/2022/2972275
Małyszko J, Kozłowska K, Kozłowski L. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924-36. DOI: https://doi.org/10.1093/ndt/gfw338
Sawinski D. The kidney effects of hematopoietic stem cell transplantation. Adv Chronic Kidney Dis. 2014;21(1):96-105. DOI: https://doi.org/10.1053/j.ackd.2013.08.007
Singh N, McNeely J, Parikh S, Bhinder A, Rovin BH, Shidham G. Kidney complications of hematopoietic stem cell transplantation. Am J Kidney Dis. 2013;61(5):809-21. DOI: https://doi.org/10.1053/j.ajkd.2012.09.020
Abudayyeh A, Wanchoo R. Kidney Disease Following Hematopoietic Stem Cell Transplantation. Adv Chronic Kidney Dis. 2022;29(2):103-115.e1. DOI: https://doi.org/10.1053/j.ackd.2021.11.003
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58-66. DOI: https://doi.org/10.1056/NEJMra1214243
Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(6):961-73. DOI: https://doi.org/10.1053/j.ajkd.2008.11.034
Forni LG, Darmon M, Ostermann M, Oudemans-van Straaten HM, Pettila V, Prowle JR, et al. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43(6):855-66. DOI: https://doi.org/10.1007/s00134-017-4809-x
Macedo E, Mehta RL. Renal recovery after acute kidney injury. Contrib Nephrol. 2016;187:24-35. DOI: https://doi.org/10.1159/000443289
Kellum JA. How can we define recovery after acute kidney injury? Considerations from epidemiology and clinical trial design. Nephron Clin Pract. 2014;127(1-4):81-8. DOI: https://doi.org/10.1159/000363681
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-78. DOI: https://doi.org/10.1200/JCO.2007.15.0177
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854. DOI: https://doi.org/10.1056/NEJMra0904569
Puri I, Sharma D, Gunturu KS, Ahmed AA. Diagnosis and management of tumor lysis syndrome. J Community Hosp Intern Med Perspect. 2020;10(3):269-272. DOI: https://doi.org/10.1080/20009666.2020.1761185
Perissinotti AJ, Bishop MR, Bubalo J, Geyer MB, Goodrich A, Howard SC, et al. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: results of a modified Delphi panel. Cancer Treat Rev. 2023;120:102603. DOI: https://doi.org/10.1016/j.ctrv.2023.102603
Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578-86. DOI: https://doi.org/10.1111/j.1365-2141.2010.08143.x
Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115-24. DOI: https://doi.org/10.1097/MAJ.0b013e31812dfe1e
Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15-25. DOI: https://doi.org/10.1007/s40620-017-0392-z
Tang C. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol. 2023;19(1):53-72. DOI: https://doi.org/10.1038/s41581-022-00631-7
Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do. Kidney Int. 2020;97(1):62-74. DOI: https://doi.org/10.1016/j.kint.2019.07.022
Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep. 2017;2(1):108-23. DOI: https://doi.org/10.1016/j.ekir.2016.09.055
Izzedine H, Perazella MA. Anticancer drug-induced acute kidney injury. Kidney Int Rep. 2017;2(4):504-14. DOI: https://doi.org/10.1016/j.ekir.2017.02.008
Downloads
Published
How to Cite
Issue
Section
